Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. (HNGE) reported an insider equity transaction by its Chief Financial Officer on 11/18/2025. The filing shows that 34,903 shares of Class A common stock were disposed of at $40.84 per share in a transaction classified as exempt under Section 16b-3(e). These shares were withheld and cancelled to cover federal and state tax obligations arising from the vesting of restricted stock units, rather than being sold in the open market.
After this tax-withholding event, the CFO beneficially owns 525,248 shares of Class A common stock. This total includes 781 shares acquired on November 14, 2025 through the company’s employee stock purchase plan.
A stockholder of HNGE filed a Form 144 notice to sell up to 3,813 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $166,257.86. The filing reports that 37,919,155 shares of common stock were outstanding. The shares to be sold were acquired as restricted stock from the issuer on 10/01/2024 (2,188 shares) and 01/01/2025 (1,625 shares), both fully paid in stock rather than cash.
The notice also discloses that Kristina Leslie, at a listed San Francisco address, sold 2,187 shares of common stock on 11/18/2025 for gross proceeds of $88,476.40. The proposed new sale is expected around 11/19/2025 on the NYSE, and the signer represents they are not aware of undisclosed material adverse information about the issuer.
HNGE has a shareholder filing a Rule 144 notice to sell 351,045 Class A shares through Merrill Lynch on the NYSE, with an approximate sale date of 11/18/2025.
The filing lists an aggregate market value of 14,336,677.8 for the shares to be sold and notes that 37,919,155 shares were outstanding. The shares were originally acquired from the issuer in a private placement on 02/04/2020 for cash. The signer represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
HNGE shareholder filed a Rule 144 notice to sell 373,955 Class A shares, with an aggregate market value of 15,272,322.2. These shares were originally acquired from the issuer in a private placement on 02/04/2020 and paid for in cash. The proposed sales are expected to begin around 11/18/2025 through broker Merrill Lynch on the NYSE. The notice states that 37,919,155 Class A shares are outstanding, giving context for the size of this planned sale.
HNGE insider filed a Form 144 notice to sell 2,187 shares of common stock, with an aggregate market value of $88,476.40. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 11/18/2025. These shares were acquired as restricted stock from the issuer on 07/01/2024, with full payment made that same day. The filing notes that 37,919,155 shares of this class are outstanding and includes the standard representation that the seller is not aware of any undisclosed material adverse information about HNGE’s operations, including where a Rule 10b5-1 trading plan is used.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh filed an amended Schedule 13G reporting their beneficial ownership of 1,293,007 shares of Hinge Health, Inc. Class A common stock, representing 4.75% of the class. They report shared power to vote and dispose of all of these shares, with no sole voting or dispositive power. The group states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Hinge Health. The ownership percentage is calculated using 37,919,155 shares of common stock outstanding as of September 30, 2025, as referenced from the company’s Form 10-Q.
Hinge Health (HNGE) announced a share repurchase authorization. The Board approved a program to buy back up to $250.0 million of Class A common stock. The company disclosed that repurchases may occur in the open market, through privately negotiated transactions, or by other methods, and may be conducted in accordance with Rule 10b-18. The company may also use Rule 10b5-1 plans.
The authorization does not obligate Hinge Health to repurchase any specific amount and can be modified, suspended, or terminated at any time at the Board’s discretion. The company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.
Hinge Health (HNGE) reported Q3 2025 results showing strong top-line growth with ongoing investment-driven losses. Revenue reached $154.2 million, up from $100.6 million a year ago, as more clients and members used its musculoskeletal care platform. Gross profit was $126.2 million.
Operating loss was $6.1 million and net loss was $1.8 million for the quarter. For the first nine months of 2025, revenue totaled $417.1 million versus $273.1 million a year ago, while a large increase in operating expenses, including stock-based compensation, drove a net loss of $560.4 million. The company ended the quarter with $261.3 million in cash and cash equivalents and $233.8 million in marketable securities, and generated $107.5 million of operating cash flow year-to-date. Deferred revenue rose to $299.7 million, reflecting billed but not yet recognized subscription revenue.
Hinge Health, Inc. furnished an update announcing it issued a press release with financial results for the third quarter ended September 30, 2025, and will host a conference call on November 4, 2025 at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.
The company noted that the press release and call reference non-GAAP financial measures, with reconciliations to GAAP provided in the press release. Hinge Health also posted supplemental investor materials on its investor relations website (ir.hingehealth.com) and stated it uses that site to disclose material information and comply with Regulation FD.
The information was furnished under Items 2.02 and 7.01, and the press release was included as Exhibit 99.1.
Gabriel M.I. Mecklenburg, Executive Chairman & Co-Founder of Hinge Health, Inc. (HNGE), reported multiple option exercises on 09/24/2025. The Form 4 shows exercises of several stock options at strike prices between $0.30 and $1.90, resulting in the acquisition of Class B Common Stock and conversion rights into Class A Common Stock.
Following the transactions, the reporting person directly owns large quantities of Class A and Class B shares: 1,092,119 Class A shares held indirectly by GRAT and 383,592 Class A shares held indirectly by a Family Trust, plus multiple blocks of Class B shares received from exercised options (examples: 107,813, 84,320, 42,969, 60,157, 31,548). Some shares are subject to an underwriter lock-up after the issuer's IPO, and 944,250 PSUs are included among holdings and vest per award terms.